Tanezumab for the treatment of osteoarthritis pain
Copyright 2022 Clarivate..
Tanezumab is a novel humanized IgG2 monoclonal antibody that works by selectively targeting, binding to and inhibiting nerve growth factor (NGF). NGF is upregulated in response to injury and inflammation, and preclinical data indicate it plays a role in pain signaling by inducing peripheral and central sensitization. Tanezumab potentially reduces sensitization and pain by blocking the interaction between NGF and the tropomyosin receptor kinase A (TrkA), and it has been studied extensively for the treatment of pain in patients with osteoarthritis (OA). In 2017, tanezumab was granted fast track designation in the U.S. for the treatment of chronic pain in patients with OA, as well as for the treatment of chronic low-back pain. This review discusses the mechanism of action, preclinical data and phase I, II and III studies of efficacy and safety of tanezumab in patients with OA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 58(2022), 4 vom: 01. Apr., Seite 187-200 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gondal, Farva R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.04.2022 Date Revised 14.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2022.58.4.3352752 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339421118 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339421118 | ||
| 003 | DE-627 | ||
| 005 | 20231226002846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2022.58.4.3352752 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339421118 | ||
| 035 | |a (NLM)35412532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gondal, Farva R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tanezumab for the treatment of osteoarthritis pain |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2022 | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2022 Clarivate. | ||
| 520 | |a Tanezumab is a novel humanized IgG2 monoclonal antibody that works by selectively targeting, binding to and inhibiting nerve growth factor (NGF). NGF is upregulated in response to injury and inflammation, and preclinical data indicate it plays a role in pain signaling by inducing peripheral and central sensitization. Tanezumab potentially reduces sensitization and pain by blocking the interaction between NGF and the tropomyosin receptor kinase A (TrkA), and it has been studied extensively for the treatment of pain in patients with osteoarthritis (OA). In 2017, tanezumab was granted fast track designation in the U.S. for the treatment of chronic pain in patients with OA, as well as for the treatment of chronic low-back pain. This review discusses the mechanism of action, preclinical data and phase I, II and III studies of efficacy and safety of tanezumab in patients with OA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Analgesic drugs | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Nerve growth factor (NGF) inhibitors | |
| 650 | 4 | |a Osteoarthritis pain | |
| 650 | 4 | |a Rheumatic diseases | |
| 650 | 4 | |a Tanezumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Nerve Growth Factor |2 NLM | |
| 650 | 7 | |a 9061-61-4 |2 NLM | |
| 650 | 7 | |a tanezumab |2 NLM | |
| 650 | 7 | |a EQL0E9GCX1 |2 NLM | |
| 700 | 1 | |a Bilal, Jawad |e verfasserin |4 aut | |
| 700 | 1 | |a Kent Kwoh, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 58(2022), 4 vom: 01. Apr., Seite 187-200 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:187-200 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2022.58.4.3352752 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2022 |e 4 |b 01 |c 04 |h 187-200 | ||